Drugs / CR1447
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02067741 | Jun 2016 → Aug 2018 | breast adenocarcinoma | Swiss Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CR1447 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02067741 ↗ |
| Action | Activate | “Estrogen receptor beta agonist” CHEMBL3545092 ↗1“Androgen Receptor agonist” CHEMBL3545092 ↗ |
| Action | Inhibit | “acting as a steroidal aromatase inhibitor (AI)” NCT02067741 ↗ |
| Modality | Small molecule | “CR1447 (4-hydroxytestosterone [4-OHT]) is a steroidal small molecule” NCT02067741 ↗ |
| Route | Other | “transdermal CR1447” NCT02067741 ↗ |
| Target | AR | “Androgen Receptor agonist” CHEMBL3545092 ↗ |
| Target | ESR2 | “Estrogen receptor beta agonist” CHEMBL3545092 ↗ |